Rebecca Vanderpool, PhD

@rrvdpool.bsky.social

A biomedical engineer researching right ventricular function and pulmonary vascular disease. #PAH #PulmonaryCirculation Opinions are mine. #Medsky

Among adults with pulmonary arterial hypertension who had received the diagnosis less than 1 year earlier, the addition of sotatercept to background therapy resulted in a lower risk of clinical worsening than placebo. Full HYPERION phase 3 trial results and Research Summary: nej.md/4mzuaY1

The New England Journal of Medicine                   
Sotatercept for Pulmonary Arterial Hypertension within the First Year 
A Research Summary based on McLaughlin VV et al. | 10.1056/NEJMoa2508170 | Published on September 30, 2025 

Visual representations of the patients in the trial and the treatments they were assigned.                       

Read the full Research Summary at NEJM.org.

The PHun doesn’t stop there! Head over to the Poster Discussion on Late-Breaking Abstracts in 3009/3011 or Mini Symposium on Novel Models of Metabolism and Vascular Remodeling in 2009/2011. 👟👟